Prolonged Air Leak (PAL) Autologous Blood Patch Intervention Trial

Overview

About this study

The purpose of this study is to determine the safety and efficacy of autologous blood patch as a means to reduce the rate of prolonged air leak after lung cancer resection.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

-Patients who underwent elective wedge resection, segmentectomy, lobectomy, or bilobectomy for suspected non-small cell lung cancer

-Patients that have reviewed and signed the Informed Consent Form, had an opportunity to ask questions, and consent to have their de-identified data included in the study

-Patients who have an air leak on the morning of postoperative Day 3

-Age ≥ 18 years old

Exclusion Criteria: 

-Patients who undergo pneumonectomy, sleeve lobectomy, chest wall or diaphragm resection, or bilateral procedures

-Age ≤ 18 years old

-Women who are pregnant

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 3/25/2024. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Carlos Puig Gilbert, M.D.

Open for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available